SOX2、C-Myc在晚期食管鳞状细胞癌组织中的表达及其临床意义

Expression of SOX2 and C-Myc in advanced esophageal squamous cell carcinoma and its clinical significance

目的:探讨SOX2、C-Myc在晚期食管鳞状细胞癌组织中的表达情况及其与临床病理参数的关系。方法:收集我院病理科2008-2014年间64例晚期食管鳞状细胞癌患者资料,采用免疫组织化学EnVision法检测SOX2、C-Myc的表达情况。结果:64例晚期食管鳞癌患者中:男性51例(79.7%),女性13例(20.3%),男性患者远多于女性患者。发生了淋巴结转移的患者有44例,转移率为68.8%。患者远处转移率为51.6%(33/64),常见的转移部位有肺、肝、骨、胃、支气管等。免疫组化显示SOX2、C-Myc均定位于细胞核,二者在晚期食管鳞癌组织中的阳性率分别为51.56%、25%。高表达的SOX2与远处转移密切相关(P=0.046),而与其他病理参数无关;C-Myc表达升高与TNM分期密切相关(P=0.018),而与其他病理参数无关。SOX2、C-Myc蛋白共表达与晚期食管鳞癌的TNM分期(P=0.020)、N分期(P=0.027)密切相关。结论:在晚期食管鳞状细胞癌中,高表达的SOX2与远处转移密切相关,希望能成为新的治疗靶点。

Objective:To evaluate the expression of SOX2 and C-Myc in advanced esophageal squamous cell carcinoma(ESCC),and to investigate the clinical significance.Methods:Collect the data of 64 cases with advanced esophageal squamous cell carcinoma in our hospital from 2008 to 2014.The expression of SOX2 and C-Myc were detected using the immunohistochemistry EnVision method.Results:There were 51 males(79.7%) and 13 females(20.3%) among the 64 patients with advanced esophageal squamous cell carcinoma.The number of male patients was much higher than that of female patients.There were 44 patients with lymph node metastasis, the metastatic rate was 68.8%.The distant metastasis rate of patients was 51.6%(33/64),and the common sites of metastasis were lung, liver, bone, stomach, bronchus, etc.Immunohistochemistry showed that SOX2 and C-Myc were both localized in the nucleus, and the positive rates of SOX2 and C-Myc expression in advanced esophageal squamous cell carcinoma were 51.56% and 25%,respectively.The high expression of SOX2 was closely associated with distant metastasis(P=0.046),but not associated with other pathological parameters.The increased expression of C-Myc was associated with TNM stage(P=0.018),but not with other pathological parameters.The co-expression of SOX2 and C-Myc protein was closely correlated with TNM stage(P=0.020) and N stage(P=0.027) of advanced esophageal squamous cell carcinoma.Conclusion:The high expression of SOX2 is closely associated with distant metastasis in advanced esophageal squamous cell carcinoma, which is expected to be a new therapeutic target.